Analyst Price Target is $29.50
▲ +326.30% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Harpoon Therapeutics in the last 3 months. The average price target is $29.50, with a high forecast of $40.00 and a low forecast of $16.00. The average price target represents a 326.30% upside from the last price of $6.92.
Current Consensus is
The current consensus among 7 investment analysts is to buy stock in Harpoon Therapeutics. This Buy consensus rating has held steady for over two years.
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.